South Australia moves forward with ham sandwich ban and people aren't happy
Who's to say what you can or can't put in your kid's lunch box? A lot of people, actually. Just look at the recent stories published about unwanted notes left by teachers and day care workers.
Unhealthy items are often the reason for the left messages, but what's unhealthy exactly? Lollies? Fairy bread? Sure. But what about the good old ham sandwich?
Apparently that's on the list too, and it has caused such a stir in recent times that South Australia has now moved to ban all advertisements that mention the trusty cold meat staple.
Want to join the family? Sign up to our Kidspot newsletter for more stories like this.
Is ham really that bad in a sandwich? Image: iStock
South Australia's ban on ham sandwiches
Recent reports have confirmed that advertisements on ham and salad sandwiches will be banned on South Australia's public transport in a bid to push healthier eating in children and tackle the ongoing issue of adult and childhood obesity in their state.
The ban, which is said to be enforced from July 1st 2025, will not only include cold meats like ham being plastered on the state's buses, trains and trams but will also see any images or mentions of chocolate, lollies, ice cream, soft drinks and other confectionery removed from public viewing.
According to the Australian Association of National Advertisers, it's a "blanket ban" that is uncalled for and a little extreme.
'As it stands, this policy bans all processed meats, which means a simple ham salad sandwich can't be advertised.' AANA CEO Josh Faulks said, according to news.com.au.
'This simply doesn't make sense and the government should be making evidence-based decisions, not blanket bans that don't align with nutritional science.'
RELATED: Parents rage after school bans meat in lunch boxes
Is this really necessary?
When looking at South Australian statistics alone, recent figures have highlighted that 63 per cent of adults and 35 per cent of children across the state are overweight or obese.
If the ban comes into effect, the AANA wants the government to adopt what it calls a 'science-based approach' by using nutrient profiling scoring criteria to determine which foods should be restricted.
For Australian paediatric nutritionist, Susie Burrell, the move is certainly one people in the industry saw coming given recent news about experts wanting parents to stop putting the humble hambo in their kids' lunch boxes.
"The World Health Organisation classifies processed meats including salami, sausages, bacon and devon as Grade 1 carcinogen's, which means that increased consumption is associated with an increased risk of developing cancer, bowel cancer in particular. There are chemicals in both red and processed meat which can damage the lining of the gut which can lead to bowel cancer," Susie tells Kidspot.
"Like many areas of nutrition though, the reality is a little bit more complicated. Not everyone who consumes processed meats will develop bowel cancer. Rather, whether or not individuals develop cancer will depend on a range of other variables including genetics, usual dietary intake, alcohol consumption, among other factors that increase or reduce the risk of cancers developing."
For Susie, a ham sandwich is totally fine to put in your child's lunch box and shouldn't be the main concern for childhood obesity, leading to bans such as the one in South Australia.
"In the diet of an individual who consumes large portions of red and processed meat, as part of a high fat diet with minimal fresh food, the risk overall is greater. While for someone who consumes a ham sandwich on wholegrain bread each day, along with 7-10 serves of fresh fruit and vegetables and minimal processed foods, the risk is significantly lower," she explains.
"This is the issue with targeting a single food within a mixed and varied diet which may offer many other protective factors against cancer development. There is also a big difference in the range of processed meats you can find - some are low in fat; some are nitrate free and some have much more protein and less sodium – they are not all and one the same thing."
The ban covers advertisements on Adelaide's transportation network. Image: NewsWire / Kelly Barnes
How other states should move forward
Back in 2022, the Cancer Council issued a grim warning to parents to stop putting cold, processed meats in their children's sandwiches at school because of the link to increased risk of bowel and stomach cancer.
'We know that ham is a lunch box staple for many families, however, Cancer Council recommends that we limit or avoid processed meats because of their link to increasing the risk of bowel and stomach cancer,' a release from the Cancer Council said at the time.
The Australian Dietary Guidelines said these foods are deemed discretionary, like cakes and biscuits, and should therefore only be eaten occasionally.
For Susie, she'd like to see more manufacturers thinking of better options to put on the market rather than pile on stress for parents about what their children can or can't eat.
"Let's use public health messaging to target the manufacturers of processed meats to make better products that are lower in salt, preservative free and to create innovative products that are better for everyone's health," she says.
"That is where the energy of public health organisations is much better spent and leave the consumer messaging to the clinicians who are much more familiar with the daily stressors the average family is dealing with, especially in relation to packing an appealing and nutritious school lunchbox."
Originally published as South Australia moves forward with ham sandwich ban and people aren't happy
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
an hour ago
- ABC News
Birth trauma link to poor mental health
Becoming a mum is supposed to be a joyous occasion, but sadly for many women, the injuries they sustain giving birth cause serious physical and psychological issues. News surveys found delays in getting a timely diagnosis are compounding the problems. Those who struggle to get a diagnosis are 2.4 times more likely to experience suicidal thoughts. Here's National Health Equity reporter, Caitlyn Gribbin. Caitlyn Gribbin: Kristy Keefe is soaking up the special moments with her dinosaur-loving son. Riley is six years old and the Brisbane mum's second child. Kristy Keefe: I absolutely love motherhood. I feel like I was made to be a mother. Caitlyn Gribbin: But in the months following Riley's birth, things were very different. He was unexpectedly born at home and a medical emergency followed. Kristy Keefe: They found out that I had a fourth-degree tear because of my placenta being stuck. I was hemorrhaging quite bad. Caitlyn Gribbin: The birth injury led to incontinence, triggering feelings of dread and isolation for Kristy Keefe. Kristy Keefe: Really anxious. I didn't want to be left alone with my baby. And I had times where I thought about ending my life. Caitlyn Gribbin: It's been more than a year since a landmark inquiry in New South Wales heard traumatic birth experiences, including pelvic floor damage and incontinence, can have tragic mental health consequences. Now, a new survey from advocacy group Birth Trauma Australia finds the longer it takes to diagnose those injuries, the more catastrophic the consequences. Chief Executive, Amy Dawes. Amy Dawes: We found that women that had struggled to get a diagnosis, they were 2.4 times more likely to experience suicidal thoughts. I have heard firsthand accounts of women sharing their experiences of being in a really dark place and struggling to get care. Nisha Khot: It is a complete disaster. I mean, it's just a sign that we have failed women. Caitlyn Gribbin: Nisha Khot is president-elect of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists. She points to Australian Institute of Health and Welfare Research showing suicide is one of the leading causes of maternal death during pregnancy and up to six weeks after pregnancy. And while it's not known if those women were suffering from birth trauma, the obstetrician believes they are intertwined. Nisha Khot: If you have physical trauma and you're struggling with your body functions, that is going to affect you psychologically as well. That has such huge implications for you to be able to just lead a normal life. You can't do any of these things because of your incontinence. That is bound to have a huge impact on your mental well-being. How could it not? Caitlyn Gribbin: State governments in New South Wales, Victoria, Queensland and Western Australia say they're spending new money on perinatal mental health care and birth trauma policies. Advocates say it's positive to see more investment and education of health care workers, but more is needed. Kristy Keefe: You love cuddles, don't you? Yeah, and mum, look! Yeah! Caitlyn Gribbin: And after her struggle to get help in the public health system, Kristy Keefe agrees. Kristy Keefe: If I didn't go and get that help and pay all that money to go and see that private gynaecologist, that maybe I wouldn't be here today. Sabra Lane: Brisbane mum, Kristy Keefe, ending Caitlyn Gribbin's report. And if this story has raised concerns for you or anyone you know, you can call Lifeline on 13 11 14.
ABC News
4 hours ago
- ABC News
Despair over owl deaths as regulator in fourth year of rat bait review
Councils across Western Australia have joined animal welfare groups in a campaign to reduce the use of common rat and mouse baits, citing the devastating impact on native birds and animals. Second-generation anticoagulant rodenticides (SGARs), such as ratsak, are readily available on supermarket shelves and are a common option for people targeting rat and mouse infestations. But the poisons have a devastating effect on native birds, including owls, that receive lethal or crippling doses when they consume already-poisoned rodents. The national chemical regulator, the Australian Pesticides and Veterinary Medicines Authority (APVMA), has been reviewing the availability of the poisons since 2021, with an outcome expected in weeks. But wildlife advocates say the daily impact on wildlife shows the review has not proceeded quickly enough. The poisons have killed at least 60 owls in and around WA's South West in recent months. Capes Raptor Centre rehabilitation coordinator Anne-Marie Orkasalo said the baits caused long and painful deaths. "It essentially stops the blood clotting so the animal keeps on bleeding, and of course, that's a very long process," she said. Owl researcher Boyd Wykes established Owl Friendly Margaret River in 2018 to raise awareness of the damage that toxic rat baits caused. Dr Wykes said he believed properly regulating baits would expose the full scope of their impact. "These things are being sold at supermarkets and hardware stores, and if [everyone has] got a rat or a mouse problem, the first thing they're doing is going and buying these rat poisons," he said. "We think it's across a broad range of wildlife, and we think once we control these things, we'll see a resurgence in a whole lot of wildlife. "I think we're going to find rodenticides were just a hidden problem having a huge impact." The slow-moving nature of the review has led several local governments to reduce their use of baits ahead of the APVMA's ruling. The Shire of Augusta-Margaret River was one of the first, ending its use of SGARs in 2020. Chief executive Andrea Selvey said concerned citizens fuelled the move and the shire was now working to educate residents on alternative options. "Some initiatives are very simple: how we manage our waste, our rubbish, compost making sure it's secure and not accessible by rodents," she said. "Some community members have installed owl roosting boxes to encourage owls on their property, and they become part of the rodent control measures." The APVMA started its chemical review of SGARs in 2021 and assessment phase in February 2022. The assessment had a statutory time frame of 26 months for completion, which lapsed in mid-2024, and its drafted decision is several months overdue. In a statement to the ABC, an APVMA spokesperson said it had revised its predicted publication date due to "complex scientific assessments" and consideration of legislative options. "The APVMA is currently finalising the documents for our proposed regulatory decision for the anticoagulant rodenticides review," the spokesperson said. "We expect to publish this in the coming weeks, which will start a three-month public consultation period."
News.com.au
6 hours ago
- News.com.au
Dr Boreham's Crucible: Microba Life Sciences
When Russian author Aleksandr Solzhenitsyn said the battle between good and evil runs through every man - ok, person - he was not talking about the trillions of bacteria that reside in the gut. But he may well have been, because this thriving ecosystem of bugs can make us very ill - or promote healthy functions such as digestion and immunity. In the main, they do the good stuff. Microba's reason for being is to help chronically unwell people by addressing their microbiome, which CEO Dr Luke Reid dubs the critical 'missing organ'. Gut health and the microbiome have been a trendy 'wellness' area, exemplified by the proliferation of probiotic supplements. 'But no one has truly medicalised the unequivocal science that has built over the last decade on this forgotten organ, and how we can treat and manage it,' Reid says. Microba has commercialised two clinical tests, to assess and manage gastro-intestinal (GI) patients. 'We have been at the forefront of clinical microbiome diagnostics for the last seven years,' the CEO says. Microba spawns from the germ of a good idea Reid says Brisbane-based Microba 'sits at the intersection of the integrity of the gastro-intestinal tract, the structure and function of the microbiome, and the communication between the brain and the gut.' The company's flagship Metaxplore tests assess a range of markers to assess the gastro-intestinal tract. 'It then distills that into a clear report with findings and - most importantly - what the clinicians can in terms of diet, dietary supplementation, targeted medications and specific lifestyle changes,' Reid says. Microba was formed in 2017 based on intellectual property acquired from the University of Queensland. The patents built on the work of the co-founders Prof Philip Hugenholtz and Prof Gene Tyson at institutions including University of California Berkeley, Massachusetts Institute of Technology and the Joint Genome Institute. Reid was an associate director of Uniquest Pty Ltd and held roles with plant genetics leader Dupont Pioneer, and biotechnology innovator Novozymes. The company's deputy chair, Prof Ian Frazer, co-invented the Gardasil and Cervarix cervical cancer vaccines. The company launched its first non-diagnostic product, Microba Insight, in Australia in July 2018. This delivered the world's 'largest clinically applicable, proprietary microbiome dataset'. Microba listed on April 5, 2022, at a subscription price of 45 cents, with the initial public offer raising $30 million. The company launched its core clinical testing products Metaxplore and Metapanel, in February 2023 and March 2024 respectively (see below). In November 2023, Microba expanded into the UK with the strategic acquisition of private UK microbiome testing business Invivo Clinica, for an upfront GBP5 million ($A10.4 million). In late 2022, ASX-listed pathology giant Sonic Healthcare invested $17.8 million to acquire a 19.99% holding in Microba. In October 2024, the company sold its non-core research services business and this year has been discontinuing legacy products. In late April, Microba entered a partnership with the Colonoscopy Clinic, one of Australia's largest private gastro-intestinal operations, seeing about 10,000 patients a year. The guts of Microba The Microba business is based on a proprietary database of one million microbial genomes, covering thousands of species. Rather than 'dying in a sea of opportunity', the company has focused on gastro-intestinal disease. 'Ninety-five per cent of those organisms live in the gut and will act there first, before they have their systemic impact through the body,' Reid says. Metapanel is the 'first line' test to determine whether the patient has a pathogen that can be treated simply with antibiotics. While other screening panels are available, they only detect 15 to 25 pathogens, whereas Metaxplore can deal with more than 100. 'Metapanel rules out the simplest root causes first - 'bad guy? yes or no' - while Metaxplore deals with the complexity of everything else that could be wrong with that patient's gastro-intestinal and microbiome health,' Reid says. As with a standard pathology assay, clinicians refer both tests to patients. The patient sends back a stool test sample with the supplied kit. The clinicians interpret the reports - which are designed to be 'simple and actionable' - just before the patient visits. Metapanel study In May, Microba released the 'compelling' results of a study called Metapanel, which analysed 889 test results from patients' long-term gastro-intestinal symptoms. The results showed that 20% of patients (178 of them) tested positive for a pathogen that can cause gastro-intestinal infection. Of the pathogens detected, 78% were missed by routine pathology tests. Furthermore, 58% of tests showed abnormal microbiome results, supporting referral to a Metaxplore test for further investigation. All the patients treated showed 'complete symptom resolution' in an independent study. All results are reviewed by an expert pathologist that recommends treatments, including antibiotic selection. Metaxplore study A week later, Microba announced the results of a 'landmark' gastro-intestinal study, covering more than 4600 patients undergoing Metaxplore testing. Of these, 71.4% had 'actionable results' with 42% testing positive for abnormal microbiome markers linked to gastro-intestinal health. About 10% tested positive for gastro-intestinal markers, such as inflammation, pancreatic insufficiency or stool blood. Almost 20% tested positive for multiple markers (microbiome and gastro-intestinal). The crux is that 65% of patients reported health improvements after following their doctor's advice (based on the Metaxplore findings). Eyes on the US prize Currently Metaxplore is sold in Australia and in the UK, while Metapanel is available locally via Sonic. Reid says Microba has a 'well considered plan' for US rollout. 'The US market is a big pie, so we have a plan to take it one slice and one bite at a time,' Reid says. 'Our strategy is to start in one state and one city, with a small team. In effect we will replicate what we did in the UK, accessing influential clinicians and then opening up to more.' The company estimates a total addressable market of $25 billion covering 82 million patients, across the US, the UK, Germany, Italy, Spain, France and Australia. 'Bugs as drugs' For the last five years, Microba has developed a pipeline of novel therapeutics across three programs. Think of them as prescription probiotics, or 'bugs as drugs'. The company has completed a phase I study for ulcerative colitis; and has pre-clinical programs for immune-oncology and auto-immune conditions. Ulcerative colitis is one of the two major forms of irritable bowel disease, which results in inflammation and ulcers (sores) in the digestive tract. It is a debilitating, chronic condition - and poorly treated. In December 2023, the company reported the phase I study of 32 healthy volunteers, showing Microba's drug candidate MAP-315 was 'well tolerated at both low and high doses'. The company plans an investigational new drug application to the US Food and Drug Administration, to enable a phase II trial. Finances and performance In late June, Microba completed a $14.5 million capital raise, with a $12.5 million two-tranche placement and a fully-underwritten share plan for $2 million, both at nine cents a share, a 22% discount. The shares come with options, exercisable at 14 cents within two years. Sonic Healthcare ponied up $4.1 million and has indicated a further potential commitment of $4.1 million more. Microba posted record core test sales in the March quarter. Locally, the company sold 3,225 Metaxplore tests, more than triple the previous period, taking the annualised run rate to 12,900 tests, also up 200%. In the UK, the company sold 246 Metaxplore tests, with turnover doubling between February and March. Meanwhile, the company achieved 212 local Metapanel sales, up 1,827%. Cash receipts totalled $4.23 million for the quarter, up 5.2% on a year previously. Revenue fell 14% to $3.4 million, reflecting an 84% decline in (legacy) research work. Microba guided to revenue of $15.25 million to $16.25 million for the year to June 30, 2025, and in late June narrowed this to $15.4 million to $16 million. Management expects Australia and the UK to be break-even this year. Post raising, the company has a proforma cash position of $26.29 million. Over the last 12 months, Microba shares have wavered between 32 cents (January 28, 2025) and eight cents (July 2 this year). The Microba register includes Thorney Investments (Tiga Trading) and Perennial Value Management. Who's payin' … just sayin' Normally patients are like your columnist with the first shout: short arms and long pockets. Unlike most medical diagnostic plays, Microba is not exactly hanging out for US reimbursement because patients are willing to stump up because they're in so much long-term pain. 'We don't need it to have a ginormous business,' Reid says. 'There is a hungry, cash-pay market that's bigger than people understand.' That said, the company wouldn't exactly snub US reimbursement. Microba's price modelling settled on $470 for Metaxplore in Australia. In the UK, the price is £399 ($A830) per test. In the US, the price looks like coming in at anywhere between US$450 and US$800 ($688 to $1224). Currently sold just in Australia via Sonic, a Metapanel test sells for $345. The obvious gambit is to bundle the tests in a 'two-for-one' special, involving only one medical consultation. This is something for the future. Dr Boreham's diagnosis: Reid says after years of work and investment, Microba has transitioned from being 'R&D heavy' to 'capital light, partnering and revenue-focused'. 'We have a significant revenue base that is growing quickly,' he says. 'We aren't waiting for the promise of approvals or reimbursement; we have real product in the market getting value and delivering clinical results.' While Microba estimates a US$25 billion a year market for 82 million tests, it hones the 'addressable' market within three years to 18 million tests and an 'obtainable' market of two million assays. Do the sums and the revenue rewards are still humungous. In the US alone, 37 million patients present each year with a range of symptoms and half of them are not resolved. 'We only need to unlock a fraction of a percent to meet our business objectives,' Reid says. In the meantime, Microba shares have more than halved over the last year and a crica $50 million valuation does not do justice to these achievements. But in the pantheon of ASX biotechs, this is not a unique story and patient investors should be rewarded in the fullness of time. At a glance: ASX Code: MAP Share price: 9.4 cents Market cap: $48 million Chief executive officer: Dr Luke Reid
